Canagliflozin
From Proteopedia
(Difference between revisions)
| Line 10: | Line 10: | ||
<scene name='10/1023629/Cv/2'>Human SGLT2-MAP17 complex with Canagliflozin</scene> ([[8hdh]]). | <scene name='10/1023629/Cv/2'>Human SGLT2-MAP17 complex with Canagliflozin</scene> ([[8hdh]]). | ||
| - | <scene name='10/1023629/Cv/4'>Canagliflozin</scene>. | + | <scene name='10/1023629/Cv/4'>Canagliflozin binding site</scene>. |
See also: | See also: | ||
Revision as of 12:43, 16 April 2024
| |||||||||||
References
- ↑ "Canagliflozin Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.
- ↑ "Integrity - Clarivate"
- ↑ Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. PMID:32064793 doi:10.1002/psp4.12498
- ↑ Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? Drugs. 2021 Aug;81(12):1365-1371. PMID:34232488 doi:10.1007/s40265-021-01559-1
- ↑ Klement A (20 January 2014). "Tubuläre Senkung des Blutzuckers bei Diabetes mellitus: Invokana". Österreichische Apothekerzeitung (in German) (2/2014): 20f.
